Development of 1h mrs biomarkers for tracking early predementia Alzheimer disease

Kejal Kantarci; Gregory A. Jicha

doi:10.1212/WNL.0000000000006839

Development of ¹h mrs biomarkers for tracking early predementia Alzheimer disease

Kejal Kantarci
, Gregory A. Jicha

Research output: Contribution to journal › Editorial

9 Scopus citations

Original language	English
Pages (from-to)	209-210
Number of pages	2
Journal	Neurology
Volume	92
Issue number	5
DOIs	https://doi.org/10.1212/WNL.0000000000006839
State	Published - Jan 29 2019

Bibliographical note

Funding Information:
K. Kantarci serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc.; receives research support from Avid Radiopharmaceuticals and Eli Lilly; and is funded by the NIH (R01 AG040042 [PI], U01 NS100620 [PI], RF1 AG57547 [PI], U54 AG 44170/Project 2 [PI]) and the Alzheimer’s Drug Discovery Foundation. G. Jicha is funded by the NIH (R01 AG038651, R01 AG042419, R01 AG054130, P30 AG028383, R01 HD064993, R01 NR014189, UH2 NS100606, U19AG010483, UL1TR000117) and through contract research with AbbVie, Alltech, Biohaven, Esai, Janssen, Novartis, and Suven. Go to Neurology.org/N for full disclosures.

Funding

K. Kantarci serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc.; receives research support from Avid Radiopharmaceuticals and Eli Lilly; and is funded by the NIH (R01 AG040042 [PI], U01 NS100620 [PI], RF1 AG57547 [PI], U54 AG 44170/Project 2 [PI]) and the Alzheimer’s Drug Discovery Foundation. G. Jicha is funded by the NIH (R01 AG038651, R01 AG042419, R01 AG054130, P30 AG028383, R01 HD064993, R01 NR014189, UH2 NS100606, U19AG010483, UL1TR000117) and through contract research with AbbVie, Alltech, Biohaven, Esai, Janssen, Novartis, and Suven. Go to Neurology.org/N for full disclosures.

Funders	Funder number
National Institutes of Health (NIH)	U01 NS100620, R01 AG040042, RF1 AG57547
National Institutes of Health (NIH)
Alzheimer's Drug Discovery Foundation	U19AG010483, P30 AG028383, R01 NR014189, UL1TR000117, R01 AG054130, R01 HD064993, R01 AG042419, UH2 NS100606, R01 AG038651
Alzheimer's Drug Discovery Foundation
Eli Lilly and Company

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000006839

Cite this

@article{29d3e113e84d4a2a8e41bfbc76849d75,

title = "Development of 1h mrs biomarkers for tracking early predementia Alzheimer disease",

author = "Kejal Kantarci and Jicha, \{Gregory A.\}",

note = "Funding Information: K. Kantarci serves on the data safety monitoring board for Takeda Global Research \& Development Center, Inc.; receives research support from Avid Radiopharmaceuticals and Eli Lilly; and is funded by the NIH (R01 AG040042 [PI], U01 NS100620 [PI], RF1 AG57547 [PI], U54 AG 44170/Project 2 [PI]) and the Alzheimer{\textquoteright}s Drug Discovery Foundation. G. Jicha is funded by the NIH (R01 AG038651, R01 AG042419, R01 AG054130, P30 AG028383, R01 HD064993, R01 NR014189, UH2 NS100606, U19AG010483, UL1TR000117) and through contract research with AbbVie, Alltech, Biohaven, Esai, Janssen, Novartis, and Suven. Go to Neurology.org/N for full disclosures.",

year = "2019",

month = jan,

day = "29",

doi = "10.1212/WNL.0000000000006839",

language = "English",

volume = "92",

pages = "209--210",

number = "5",

}

TY - JOUR

T1 - Development of 1h mrs biomarkers for tracking early predementia Alzheimer disease

AU - Kantarci, Kejal

AU - Jicha, Gregory A.

N1 - Funding Information: K. Kantarci serves on the data safety monitoring board for Takeda Global Research & Development Center, Inc.; receives research support from Avid Radiopharmaceuticals and Eli Lilly; and is funded by the NIH (R01 AG040042 [PI], U01 NS100620 [PI], RF1 AG57547 [PI], U54 AG 44170/Project 2 [PI]) and the Alzheimer’s Drug Discovery Foundation. G. Jicha is funded by the NIH (R01 AG038651, R01 AG042419, R01 AG054130, P30 AG028383, R01 HD064993, R01 NR014189, UH2 NS100606, U19AG010483, UL1TR000117) and through contract research with AbbVie, Alltech, Biohaven, Esai, Janssen, Novartis, and Suven. Go to Neurology.org/N for full disclosures.

PY - 2019/1/29

Y1 - 2019/1/29

UR - https://www.scopus.com/pages/publications/85065533549

UR - https://www.scopus.com/pages/publications/85065533549#tab=citedBy

U2 - 10.1212/WNL.0000000000006839

DO - 10.1212/WNL.0000000000006839

M3 - Editorial

C2 - 30610092

AN - SCOPUS:85065533549

SN - 0028-3878

VL - 92

SP - 209

EP - 210

JO - Neurology

JF - Neurology

IS - 5

ER -